Akers Biosciences Inc (NASDAQ:AKER)
Aegis Capital Initiates Coverage on Akers Biosciences Inc (NASDAQ:AKER)’s stock to Buy with the price target of $11. This rating was issued on 6/09/14. The stock recently closed its previous session at $0.3 by showing a percentage change of -6.91% from its previous day closing price of $0.32.
Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.
Akers Biosciences Inc (NASDAQ:AKER) currently has a consensus Price Target of $. While some analysts have a High Price target for the stock of $ and a Low Price Target of $.
Several sell side analysts reviewed their recommendations on Akers Biosciences Inc (NASDAQ:AKER) where Estimate analyst have rated the stock as Strong Buy, 1.56 rated the stock as Hold, 1.19 analysts reported Underperform and 0.84 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)
In the last Quarter, Akers Biosciences Inc (NASDAQ:AKER) reported its Actual EPS of $-0.2/share. The analysts offering Earnings Estimates for the company were believing that Akers Biosciences Inc (NASDAQ:AKER) could bring EPS of $0.06/share. The difference between Actual EPS and Estimated EPS was -0.26 Percent. Thus the company showed an Earnings Surprise of -433.3 Percent.
Akers Biosciences Inc (NASDAQ:AKER) has a market capitalization of 20.77 Million. The stock traded with the volume of 3.22 Million shares in the last trading session. The stock touched its high share price of $1.82 on 10/13/17 and the stock also touched its Lowest price in the last 52-weeks of trading on 12/22/17 as $0.12. The company has a 1 Year high price target of $4. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -1.98%. The Moving Average SMA50 is 7.2% while SMA200 is -27.99%.
Akers Biosciences Inc (NASDAQ:AKER) is currently showing its ROA (Return on Assets) of -90.7%. The Return on Investment (ROI) is at -114% while it’s Return on Equity (ROE) value stands at -114.8%. The stock currently shows its YTD (Year to Date) performance of 123.13 percent while its Weekly performance value is -26.72%. The Monthly and Yearly performances are -3.55 percent and -65.3 percent respectively. The Relative Volume value measured for Akers Biosciences Inc (NASDAQ:AKER) is 1.02. The Average Volume (3 months) is 3.15 Million.
The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. AKER has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 3.46 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.
Akers Biosciences, Inc. develops, manufactures and supplies rapid, point-of-care screening and testing products. The Company’s products primarily includes BreathScan(R), BreathScan PRO(R), METRON(R), VIVO(TM), Heparin/PF4 Antibody Serum Panels(R) and Breath Ketone. Akers Biosciences, Inc. is based in Thorofare, United States.